Alisha Chitrakar-Hall

Mrs. Alisha Chitrakar-Hall


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
ACAlisha Chitrakar-Hall
Alisha Chitrakar-Hall
MPMarta Sanz Perez
Marta Sanz Perez
SMSanjay Maggirwar
Sanjay Maggirwar
NSNatalia Soriano-Sarabia
Natalia Soriano-Sarabia
The use of antiretroviral therapy (ART) for Human Immunodeficiency Virus (HIV) treatment has been highly successful in controlling plasma viremia to undetectable levels. However, a complete cure for HIV is hindered by the presence of replication-competent HIV, integrated in the host genome, that can persist long term in a resting state called viral latency. Resting memory CD4+ T cells are considered the biggest reservoir of persistent HIV infection and are often studied exclusively as the main target for an HIV cure. However, other cell types, such as circulating monocytes and tissue-resident macrophages, can harbor integrated, replication-competent HIV. To develop a cure for HIV, focus is needed not only on the T cell compartment, but also on these myeloid reservoirs of persistent HIV infection. In this review, we summarize their importance when designing HIV cure strategies and challenges associated to their identification and specific targeting by the “shock and kill” approach.